Tirzepatide for Obesity Treatment and Diabetes Prevention
Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Authors
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Leigh Perreault (ORCID: https://orcid.org/0000-0002-1481-7535)
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- Mathijs C. Bunck (ORCID: https://orcid.org/0000-0002-2862-6705)
- John P.H. Wilding (ORCID: https://orcid.org/0000-0003-2839-8404)
- Louis J. Aronne (ORCID: https://orcid.org/0000-0002-9890-9401)
- Bruno Halpern (ORCID: https://orcid.org/0000-0003-0973-5065)
- Irina Jouravskaya
- Shuyu Zhang (ORCID: https://orcid.org/0000-0003-1419-3635)
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
- Nadia N. Ahmad
- Ramakrishna Battula
Institutions
- University College Dublin (IE)
- University of Liverpool (GB)
- Eli Lilly (United States) (US)
- University of Toronto (CA)
- Cornell University (US)
- Diabetes Australia (AU)
- Yale Cancer Center (US)
- Yale University (US)
- Washington Center for Weight Management and Research (US)
- Weill Cornell Medicine (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1056/nejmoa2410819
- Citations
- 306
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 137.03
Funders
- Eli Lilly and Company